Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 18/20 | 0.41 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13314909 | 0.88 | GCK (0.42) | GCKGRAMD1A | |
| SCHEMBL3534454 | 0.87 | GRAMD1A (0.39) | GCKGRAMD1AALDH1A1 | |
| SCHEMBL10756234 | 0.79 | RAB9A (0.38) | GRAMD1AALDH1A1 | |
| SCHEMBL3538844 | 0.79 | GAA (0.39) | GRAMD1AALDH1A1 | |
| SCHEMBL3537071 | 0.77 | ALOX15 (0.44) | GRAMD1AALDH1A1 | |
| SCHEMBL10764703 | 0.76 | GRAMD1A (0.43) | GCKGRAMD1AALDH1A1 | |
| SCHEMBL3537610 | 0.76 | GRAMD1A (0.45) | GCKGRAMD1AALDH1A1 | |
| SCHEMBL3534502 | 0.75 | GAA (0.43) | GRAMD1AALDH1A1 | |
| SCHEMBL10825512 | 0.74 | GAA (0.43) | ALDH1A1 | |
| SCHEMBL9385295 | 0.74 | GRM5 (0.51) | GCKGRAMD1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-31 | — | — | US | claimed |
| US-20150246140-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND WAKEFULNESS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-09-03 | — | — | US | disclosed |
| US-7727979-B2 | Guanidine derivatives and their use as neuropeptide FF receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-06-01 | — | — | US | disclosed |
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | NPFFR1, OGFR, NPFFR2 | GCK 455/4885GRAMD1A 2459/4885ALDH1A1 1895/4885 |
| US-20150246140-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND WAKEFULNESS | HCRTR2, HCRTR1, NPSR1 | GCK 2943/4885GRAMD1A 4477/4885ALDH1A1 4570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.